Home › Interstitial Lung Diseases › Michigan
Interstitial Lung Diseases clinical trials in Michigan
16 studies for Interstitial Lung Diseases are looking for participants at sites in Michigan.
Cities in Michigan
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- University of Michigan, Ann Arbor
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07540988A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Ann Arbor
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT05878717Study of TX000045 in Participants With Pulmonary Hypertension Due to Interstitial Lung Disease
- Allen Park, Allen Park
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 8, 2026 · NCT07473700A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- University of Michigan, Ann Arbor
RecruitingPhase 3
Ages 40 and older · All sexes · Updated Sep 8, 2026 · NCT07201922A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- Henry Ford Health, Detroit
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 4, 2026 · NCT06968845Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- University of Michigan - Michigan Medicine, Ann Arbor
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06911632A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
- Clinical Research Site, Ann Arbor
- Clinical Research Site, Detroit
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 2, 2026 · NCT07333183DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Corewell Health Beamont Troy Hospital, Troy
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06388421Platform Clinical Study for Conquering Scleroderma
- University of Michigan, Ann Arbor
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06195072PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
- University of Michigan, Ann Arbor
RecruitingObservational study
Ages 18 to 80 · All sexes · Updated Aug 18, 2026 · NCT06855329RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- University of Michigan, Ann Arbor
RecruitingPhase 2/3
Ages 18 to 75 · All sexes · Updated Aug 17, 2026 · NCT06328777Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- Henry Ford Health, Detroit
RecruitingObservational study
Ages 21 and older · All sexes · Updated Aug 12, 2026 · NCT01915511A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
- University of Michigan, Ann Arbor
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Aug 10, 2026 · NCT07175038Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- Corewell Health Grand Rapids Hospitals - Butterworth, Grand Rapids
- Beaumont Hospital, Royal Oak, Royal Oak
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05943535A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
- Galderma Investigational Site # 8743, Ann Arbor
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 31, 2026 · NCT07047690Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease
- University of Michigan, Ann Arbor
RecruitingObservational study
Ages 18 to 90 · All sexes · Updated May 3, 2024 · NCT06397677From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.